Catalog Products » Recombinant Proteins » Growth Factors » VEGF164, Mouse (P. pastoris-expressed)
VEGF164, Mouse (P. Pastoris-expressed)

ED₅₀<6.0 ng/ml, measured by the dose-dependent stimulation of the proliferation of HUVEC cells, corresponding to a specific activity of > 1.7x 10⁵ units/mg.

VEGF164, Mouse (P. pastoris-expressed)

Recombinant mouse Vascular Endothelial Growth Factor A164 (rmVEGF-A164) produced in Pichia pastoris is a disulfide-linked homodimer containing two polypeptide chains of 165 amino acids each. A fully biologically active molecule, rmVEGF-A164 has a molecular mass of 39kDa analyzed by non-reducing SDS-PAGE and is obtained by chromatographic techniques at GenScript.
Z02690
$1545.00

Ask us a question
Product Introduction
Species Mouse
Protein Construction

Expressed with an N-terminal Met.

VEGF164 (Ala27-Arg190)
Accession # Q00731-2
Purity > 97% as analyzed by SDS-PAGE
Endotoxin Level < 1 EU/μg of protein by gel clotting method
Biological Activity ED50 < 6.0 ng/ml, measured by the dose-dependent stimulation of the proliferation of HUVEC cells, corresponding to a specific activity of > 1.7 × 105 units/mg.
Expression System P. pastoris
Apparent Molecular Weight ~39 kDa, on SDS-PAGE under non-reducing conditions.
Formulation Lyophilized after extensive dialysis against 25 mM HEPES, 150 mM NaCl, pH 7.0.
Reconstitution It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O up to 100 μg/ml.
Storage & Stability Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles.

Examples
  • VEGF164, Mouse (P. Pastoris-expressed)
    • VEGF164, Mouse (P. Pastoris-expressed)

    ED₅₀<6.0 ng/ml, measured by the dose-dependent stimulation of the proliferation of HUVEC cells, corresponding to a specific activity of > 1.7x 10⁵ units/mg.


Background
Target Background Vascular Endothelial Growth Factor (VEGF) was initially purified from media conditioned by normal bovine pituitary folliculo-stellate cells and by a variety of transformed cell lines as a mitogen specific for vascular endothelial cells. It was subsequently found to be identical to an independently discovered vascular permeability factor (VPF), which was previously identified in media conditioned by tumor cell lines based on its ability to increase the permeability of capillary blood vessels. Three mouse cDNA clones, which arise through alternative splicing and which encode mature mouse monomeric VEGF having 120, 164, or 188, amino acids, respectively, have been identified. Two receptor tyrosine kinases (RTKs), Flt-1 and Flk-1 (the mouse homologue of human KDR), both members of the type III subclass of RTKs containing seven immunoglobulin-like repeats in their extracellular domains, have been shown to bind VEGF with high affinity. The roles of the homodimers of KDR, Flt, and the heterodimer of KDR/Flt in VEGF signal transduction remain to be elucidated. In vivo, VEGF has been found to be a potent angiogenesis inducer.
Synonyms Folliculostellate cell-derived growth factor; Glioma-derived endothelial cell mitogen; VEGF-164; Vascular Permeability Factor; VPF

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.